Related Experiment Video
Updated: Aug 10, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Soft-tissue uptake of technetium-99m-MDP after prostate cryoablation
I Zucker1, N D Charkes, E J Seidmon
1Department of Nuclear Medicine, Temple University Hospital, Philadelphia, Pennsylvania, USA.
Summary
Post-prostate cryoablation, technetium-99m-methylene diphosphonate (99mTc-MDP) uptake indicates soft tissue necrosis. This imaging technique helps identify the extent of inflammation and necrosis in the prostate bed.
Area of Science:
- Nuclear Medicine
- Radiology
- Oncology
Background:
- Prostate cryoablation is a treatment for prostate cancer.
- Assessing post-treatment changes in the prostate bed is crucial for patient management.
Observation:
- Soft-tissue uptake of 99mTc-MDP was observed in the prostate bed after cryoablation.
- CT, MRI, and sonography revealed liquifactive necrosis in the prostate bed.
Findings:
- The 99mTc-MDP uptake is likely due to necrosis with neovascular hyperemia and microcalcifications.
- Three-phase scintigraphy effectively localizes soft tissue inflammation and necrosis.
Implications:
- 99mTc-MDP scintigraphy can be a valuable tool for evaluating post-cryoablation changes.
- This imaging modality aids in understanding the extent of tissue damage and healing response.
